Benedicte Lescrauwaet has over 20 years of experience in Health Economics and Outcomes Research (HE&OR) within the pharmaceutical industry in Europe, UK and Canada. Through her international career path in OR&HE of pharmaceuticals, she gained hands-on experience in the design and implementation of observational research, creation of patient reported outcome evidence, benefit quantification using patient-level data, health preference experiments and economic evaluations with the goal to compile evidence packages for submissions to Health Technology Assessment (HTA) agencies.
At Pfizer Canada (1999-2006), Benedicte learnt the nuts and bolts of health economics where she was responsible for the development of economic evaluations of launch products in various therapeutic areas (CNS, respiratory, diabetes).
Returning to Belgium, she joined Bristol-Myers Squibb Inc. (2007) where she was in charge of customizing value dossiers for selected EU markets to support market access of launch products (rheumatoid arthritis, oncology, hepatitis B). She was appointed as the European HE&OR Lead for the virology franchise (2008-2010) and designed a multi-facetted HE&OR strategy, integrating medical and access objectives, and championed multi-project deliverables in support of the value proposition of an antiviral treatment for chronic hepatitis B.
In 2010, Benedicte joined the Xintera team and has since provided strategic consulting services in outcomes research and health economics. Through her career path, she collaborated with multiple researchers to design, execute and communicate the value proposition of pipeline & in-line products within different therapeutic areas. This allows her to offer you access to a selected network of professionals, know-how and research tools.
Benedicte holds a MSc in Applied Economics from the Antwerp University, a postgraduate degree in Tropical Medicine for Bachelors in nursing from the Institute of Tropical Medicine (Antwerp, Belgium) and a Bachelor in Nursing, Public Health.
Koenraad Blot has 29 years of experience in Clinical Development and Medical Affairs within the pharmaceutical industry. He has designed and conducted Phase 1 to 4 studies across the globe and has interacted with regulatory bodies such as the FDA, EMA, MHRA and BfArM.
Having worked 3 years in Africa with Doctors Without Borders (Tigray/Ethiopia, Darfur/Sudan and Timbuctu/Mali), he worked at the Institute for Tropical Medicine (Antwerp, Belgium) from 1991 to 1992, taking care of critically ill people with AIDS. He also made major programmatic contributions to KABISA, a medical decision simulation program developed at the same institute.
In 1992, he started as Medical Advisor with Pfizer Belgium and went on to hold leadership positions in Pfizer International (1995-1998) where he first worked in European Medical Operations and subsequently supported the global trovafloxacin launch as Associate Medical Director, which involved a global rollout of randomized Phase 4 studies and training/education sessions.
During his stay at Pfizer Canada (1999-2005), he was in charge of the local Clinical Research Operations (a €20M budget) for 4 years.
In 2005, he joined Theratechnologies (Montreal, Canada) where he successfully led the Phase 3 development of tesamorelin (now marketed as Egrifta®).
Returning to Belgium in 2007, he joined elbion as Chief Medical Officer. He was Chief Medical Officer for TiGenix from 2009 to 2010.
Since 2009, Koenraad has provided scientific advice to various pharmaceutical companies as an independent consultant.
He holds an MD from Ghent University, Belgium and a Diploma in Tropical Medicine from the Prince Leopold Institute for Tropical Medicine (Antwerp, Belgium).
This website uses Go Squared Ltd’s web analytics services. Read more